C57BL/6 mice (7 weeks old) were purchased from Janvier and housed in pathogen-free conditions for one week before experiments. The mice were injected subcutaneously in the right flank with cell lines diluted in 100 µl of PBS. ACB1801 was administered to them with doses of 50, 20, and 10 mg/kg by oral gavage (per os) or 1 mg/kg by an i.p. route. Vehicle treatment was performed using methyl cellulose.
InVivoMab anti-mouse PD-1 (CD279) (BE0273) and InVivoMab rat IgG2a isotype control (BE0089) were purchased from BioXCell (Lebanon, USA), diluted in InVivoPure pH 7.0 Dilution Buffer (IP0070), and administered as indicated in the corresponding figures. Tumor volume (V) was measured using caliper every other day and estimated as follows: V (cm3) = ½ (Length × Width2). Mice were excluded if they did not develop tumors or developed tumors larger than the threshold defined in the approved experimentation protocols (volume > 2000 mm3), as previously reported (15 (link)).
InVivoMab anti-mouse PD-1 (CD279) (BE0273) and InVivoMab rat IgG2a isotype control (BE0089) were purchased from BioXCell (Lebanon, USA), diluted in InVivoPure pH 7.0 Dilution Buffer (IP0070), and administered as indicated in the corresponding figures. Tumor volume (V) was measured using caliper every other day and estimated as follows: V (cm3) = ½ (Length × Width2). Mice were excluded if they did not develop tumors or developed tumors larger than the threshold defined in the approved experimentation protocols (volume > 2000 mm3), as previously reported (15 (link)).
Free full text: Click here
